Futura Medical Share Discussion Threads

[dontshoutatonce] 23/8/2022 13:48

LBO would you please stop your writing and go away? I filtered you a long time ago but your name still comes up sadly, but without the stuff you write, thank goodness. You make it a waste of my time to even open advfn. Why not take up an outdoor sport? It doesn't have to be energetic or dangerous, - though some may encourage you to do mountaineering or skydiving - but no, just go on long, long walks or something peaceful. It may take you mind off whatever is troubling you but in a more positive way. Just try it.

[lbo] 23/8/2022 13:32

When study results are not fully published for peer review then the results and data according to the FTC can be ‘sliced and diced’



What happened next gets to the FTCs allegation that the respondents, in effect, deceptively sliced and diced the data in search of a positive marketing message. According to the complaint, the respondents subjected the data to post hoc analyses of different subgroups of test subjects. (The complaint describes a post hoc analysis as statistical analysis conducted after the data have been collected in hopes of discovering statistical relationships that suggest cause and effect.) The FTC concern is that unplanned, post hoc subgroup analyses pose a high risk of generating spurious findings.

[lbo] 23/8/2022 13:18

I wonder will FM71 be fully published for peer review?Unlike FM57 in which it seems some data was only selectively presented in an ‘illustrative’ slide presentation by Futura.

One of the criteria imposed on FM71 was ‘ will also include 20 African American patients (from a US medical centre)’



Odds estimates indicated the largest likelihood of placebo response occurred in men who were black, were younger than 45 years, had mild ED, and did not have diabetes. The likelihood of a placebo response decreased as ED duration increased.

[lbo] 23/8/2022 12:51

Again Petroc is not giving all the relevant information. FM71 is not a blinded FDA drug study with the same FDA oversight. Its only an unblinded open label medical device study for a De Novo medical device registration with no adequate control group. The participants will have known if they were using the gel or taking Tadalafil tablets. Its also clear from the December 2021 RNS that FM71 was ‘closing recruitment in the next few weeks’ which was well before the interview was published in March 2022. Also random assignment to Tadalafil or Med3000 group would have occurred well before March 2022. And would it have been ‘ethical’ for the rampers to be claiming all over the internet its a ‘Fact’ that Med3000 is ‘clinically proven’ with no disclaimers? Couldn’t some of the participants in FM71 have looked into the gel on the internet and seen those questionable claims regarding the gel that they are using? Would those rampers claims with zero disclaimers be ethical or even legal?





What do you foresee as innovations on the horizon for ED treatment in the near future?

In the next year, we don't have a whole lot more than what I just mentioned.

[petroc] 23/8/2022 12:33

LiarBO lying and posting smokescreens again. Dr Burnett is leading FM71 so it would be highly unethical for him to sing the praises of MED3000 when the results are not yet known, so it's no surprise he didn't mention it as being on the horizon. LiarBO knows this full well as we've had this argument many times over.

[lbo] 23/8/2022 10:53

I agree with Dr Burnett. If a placebo helps even one patient and the patient is fully aware they are being treated with a placebo and they are are not being treated inappropriately and there is no other more appropriate treatment then it would be a ˜valid addition to the armamentarium of treatments’. But that doesn’t make it a valid treatment in terms of shareholder returns when anyone including Reckitt can make and launch own their placebo alcohol and water gels which have the same mechanical stimulation and evaporative cooling effects.

Also like Viberect which Dr Burnett was also involved in studying. That mechanical stimulation device too according to its research also appeared to be a valid addition to the armamentarium of treatment devices that may be effective for some patients. And
any treatment that is safe and effective even for just one patient should always be seen as valid in medical terms. But unfortunately it seems in reality looking at its annual sales not enough to make it commercially valid or take anywhere near even a fraction of a percentage of the global ED treatment market. Interesting in an interview how Dr Burnett didn’t even mention that just an alcohol and water gel was supposedly the next innovation on the horizon!?








What do you foresee as innovations on the horizon for ED treatment in the near future?

In the next year, we don't have a whole lot more than what I just mentioned.

[j777j] 23/8/2022 10:39

Marvelous


tested and retested

[j777j] 23/8/2022 10:35

Pfizer really clutching at straws now




Viagra meets its greatest threat ever

[petroc] 23/8/2022 10:35

'Dermasys is a versatile and bespoke technology. Each gel is uniquely formulated using the Dermasys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action.' That's what FUM tell me and I'm more inclined to believe them than the resident stock basher, LiarBO.

[j777j] 23/8/2022 10:33

The US remains the largest market opportunity globally for ED treatments OTC and the Company is making steady progress towards completing US Food and Drug Administration ("FDA") regulatory submission for MED3000.

Patient recruitment for the FM71 study (a confirmatory study stipulated by the FDA) completed at the end of 2021 and the clinical study, including patient follow-up, is drawing to a close. The Company remains on track to be able to disclose the results in early September.

A "Human Factors" study was successfully completed in December 2021, with results able to support the regulatory submission for OTC designation, enabling Futura to finalise the OTC product label for the US filing.

The Company looks forward to further updates for shareholders during the remainder of 2022 as Futura prepares for initial launches of MED3000, further commercial agreements and the anticipated US regulatory filing by the end of September 2022.

[lbo] 23/8/2022 10:05

‘Dermasys, which is designed to penetrate the skin, whereas lubricants are designed to stay on the surface?’

Please explain what penetrates the skin after the alcohol evaporates and only water is left if there is no active drug to penetrate? Not even Futura can ever make that claim as they know it would mean that Med3000/Dermasys would have to be withdrawn from the market as a medical device if they start claiming Dermasys WITH NO API is now penetrating the skin! ROFLMAO

And FYI water based lubricants don’t stay on the surface do dry up. And so do cooling arousal gels

[j777j] 23/8/2022 09:24

Any day now folks and product access to the US OTC market would send the share price through the roof

[joestalin] 22/8/2022 17:59

I am not sure that buffoons demonstrate that degree of obsession. There is something seriously wrong here.

[petroc] 22/8/2022 17:37

Ah yes, the old 50% claim. MED3000 has been proven to work in 60% of men with ED, so there is obviously something going on. Perhaps it's the fact that MED3000 is based on Dermasys, which is designed to penetrate the skin, whereas lubricants are designed to stay on the surface? By your logic, paracetamol manufacturers can't claim that it's any better than placebo because the mechanism (what you would call 'supposed magic') has not been proved. Lol indeed, you buffoon.